Quick Answer
Altimmune, Inc. reported Stockholders Equity of $224.89 million for the year ending 2025.
- Altimmune, Inc. showed an increase of +82.1% in Stockholders Equity from 2024 to 2025.
- This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $9.94 million | Q2 2013: $13.22 million | Q3 2013: $11.35 million | Q1 2014: $8.33 million | Q2 2014: $10.86 million | Q3 2014: $18.11 million | Q1 2015: $20.02 million | Q2 2015: $18.34 million | Q3 2015: $17.67 million | Q1 2016: $15.63 million | Q2 2016: $24.25 million | Q3 2016: $136.38 million | Q1 2017: $29.10 million | Q2 2017: $75.98 million | Q3 2017: $48.83 million | Q1 2018: $40.54 million | Q2 2018: $35.81 million | Q3 2018: $39.68 million | Q1 2019: $59.32 million | Q2 2019: $56.23 million | Q3 2019: $49.38 million | Q1 2020: $41.90 million | Q2 2020: $79.52 million | Q3 2020: $199.71 million | Q1 2021: $246.44 million | Q2 2021: $241.28 million | Q3 2021: $209.26 million | Q1 2022: $184.87 million | Q2 2022: $194.54 million | Q3 2022: $205.03 million | Q1 2023: $167.73 million | Q2 2023: $167.71 million | Q3 2023: $150.40 million | Q1 2024: $172.94 million | Q2 2024: $152.53 million | Q3 2024: $133.38 million | Q1 2025: $142.16 million | Q2 2025: $161.37 million | Q3 2025: $185.60 million.
- Over the full 17 years of available data (2009 to 2025), Altimmune, Inc.'s Stockholders Equity has grown by 7,034.0%.
- Historical annual values: Fiscal year 2025: $224.89 million | Fiscal year 2024: $123.51 million | Fiscal year 2023: $194.10 million | Fiscal year 2022: $185.29 million | Fiscal year 2021: $199.14 million | Fiscal year 2020: $225.88 million | Fiscal year 2019: $45.52 million | Fiscal year 2018: $48.31 million | Fiscal year 2017: $39.40 million | Fiscal year 2016: $32.21 million | Fiscal year 2015: $43.13 million | Fiscal year 2014: $18.27 million | Fiscal year 2013: $7.34 million | Fiscal year 2012: $11.67 million | Fiscal year 2011: $15.85 million | Fiscal year 2010: $12.21 million | Fiscal year 2009: $3.15 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: